Brief: Lucid Diagnostics' Esoguard BE-1 Prospective Multicenter Clinical Validation Study Of Esoguard Esophageal Precancer Testing Accepted For Peer-Reviewed Publication
07/11/2024 13:10
Nov 7 (Reuters) - Lucid Group Inc LCID.O :
* LUCID DIAGNOSTICS' ESOGUARD BE-1 PROSPECTIVE MULTICENTER
CLINICAL VALIDATION STUDY OF ESOGUARD® ESOPHAGEAL PRECANCER
TESTING ACCEPTED FOR PEER-REVIEWED PUBLICATION
Source text: ID:nPntpx6Ra
Further company coverage: LCID.O
(Reuters.Briefs@thomsonreuters.com)
Recent news on PAVmed
See all newsBrief: Lucid Diagnostics Begins Receiving Medicare Reimbursement For Esoguard® And Closes $15 Million Financing
PAVmed Inc reports results for the quarter ended June 30 - Earnings Summary
PAVmed Inc expected to post a loss of 47 cents a share - Earnings Preview
NASDAQ RESUMED AT 11:36 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 11:21 AM